Jack Allen
Stock Analyst at Baird
(0.71)
# 3,688
Out of 4,828 analysts
42
Total ratings
31.82%
Success rate
-18.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.19 | +424.93% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $6.94 | +476.37% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.15 | +9,153.14% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $57.55 | +84.19% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $8.12 | +121.67% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $13.23 | +1,260.54% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $3.50 | +3,328.57% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.41 | +231.95% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $35.62 | +45.99% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $28.40 | +195.77% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.13 | +275.59% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $1.16 | +934.48% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.44 | +1,036.36% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $1.04 | +2,592.31% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.58 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.17 | +183.91% | 1 | Oct 7, 2021 |
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.19
Upside: +424.93%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $6.94
Upside: +476.37%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.15
Upside: +9,153.14%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $57.55
Upside: +84.19%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $8.12
Upside: +121.67%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $13.23
Upside: +1,260.54%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $3.50
Upside: +3,328.57%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.41
Upside: +231.95%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $35.62
Upside: +45.99%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $28.40
Upside: +195.77%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.13
Upside: +275.59%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $1.16
Upside: +934.48%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.44
Upside: +1,036.36%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $1.04
Upside: +2,592.31%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.58
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.17
Upside: +183.91%